These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33751617)

  • 1. Involvement of emergency medicine pharmacists in stroke thrombolysis: A cohort study.
    Roman C; Cloud G; Dooley M; Mitra B
    J Clin Pharm Ther; 2021 Aug; 46(4):1095-1102. PubMed ID: 33751617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of an emergency medicine pharmacist on door to needle alteplase time and patient outcomes in acute ischemic stroke.
    Barbour J; Hushen P; Newman GC; Vidal J
    Am J Emerg Med; 2022 Jan; 51():358-362. PubMed ID: 34823191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacist Impact on Ischemic Stroke Care in the Emergency Department.
    Gosser RA; Arndt RF; Schaafsma K; Dang CH
    J Emerg Med; 2016 Jan; 50(1):187-93. PubMed ID: 26412104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolysis for acute ischemic stroke: do patients treated out of hours have a worse outcome?
    Fang K; Churilov L; Weir L; Dong Q; Davis S; Yan B
    J Stroke Cerebrovasc Dis; 2014 Mar; 23(3):427-32. PubMed ID: 23635920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the implementation of a 24-hr stroke thrombolysis emergency treatment for patients with acute ischaemic stroke.
    Zhao J; Li X; Liang Y; Zhao L; Zhang X; Liu Y
    J Clin Nurs; 2018 May; 27(9-10):2161-2167. PubMed ID: 29345016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Impact of Implementation of a Stroke Protocol on Door-to-Needle Time in the Administration of Intravenous Tissue Plasminogen Activator.
    Hillen ME; He W; Al-Qudah Z; Wang W; Hidalgo A; Walia J
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1569-1572. PubMed ID: 28411038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACT-FAST: a quality improvement project to increase the percentage of acute stroke patients receiving intravenous thrombolysis within 60 minutes of arrival at the emergency department.
    Chiu LQ; Quek DYJ; Salihan RB; Ng WM; Othman RB; Lee CH; Oh DCT
    Singapore Med J; 2021 Sep; 62(9):476-481. PubMed ID: 32227791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes.
    Williams JM; Navin TJ; Jude MR; Levi CR
    Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Door-to-needle time for thrombolysis: a secondary analysis of the TIPS cluster randomised controlled trial.
    Hasnain MG; Paul CL; Attia JR; Ryan A; Kerr E; D'Este C; Hall A; Milton AH; Hubbard IJ; Levi CR
    BMJ Open; 2019 Dec; 9(12):e032482. PubMed ID: 31843839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times.
    Prabhakaran S; Lee J; O'Neill K
    Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):585-92. PubMed ID: 27625405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collaborative Interventions Reduce Time-to-Thrombolysis for Acute Ischemic Stroke in a Public Safety Net Hospital.
    Threlkeld ZD; Kozak B; McCoy D; Cole S; Martin C; Singh V
    J Stroke Cerebrovasc Dis; 2017 Jul; 26(7):1500-1505. PubMed ID: 28396187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shortening Door-to-Needle Time by Multidisciplinary Collaboration and Workflow Optimization During the COVID-19 Pandemic.
    Chen Y; Nguyen TN; Wellington J; Mofatteh M; Yao W; Hu Z; Kuang Q; Wu W; Wang X; Sun Y; Ouyang K; Xu J; Huang W; Yang S
    J Stroke Cerebrovasc Dis; 2022 Jan; 31(1):106179. PubMed ID: 34735901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creation of an intensive care unit and organizational changes in an adult emergency department: Impact on acute stroke management.
    Puy L; Lamy C; Canaple S; Arnoux A; Laine N; Iacob E; Constans JM; Godefroy O
    Am J Emerg Med; 2017 May; 35(5):716-719. PubMed ID: 28096032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.
    Minnerup J; Wersching H; Ringelstein EB; Schilling M; Schäbitz WR; Wellmann J; Berger K
    Stroke; 2011 Oct; 42(10):2838-43. PubMed ID: 21852612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
    Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
    Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacist Participation in Acute Ischemic Stroke Decreases Door-to-Needle Time to Recombinant Tissue Plasminogen Activator.
    Rech MA; Bennett S; Donahey E
    Ann Pharmacother; 2017 Dec; 51(12):1084-1089. PubMed ID: 28759998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of thrombolysis in acute ischaemic stroke without occlusion: an observational comparative study.
    Ajili N; Decroix JP; Preda C; Labreuche J; Lopez D; Bejot Y; Michel P; Sévin-Allouet M; Sibon I; Vergnet S; Wang A; Sanda N; Mazighi M; Bourdain F; Lapergue B
    Eur J Neurol; 2016 Aug; 23(8):1380-6. PubMed ID: 27222165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities).
    Oluwole SA; Wang K; Dong C; Ciliberti-Vargas MA; Gutierrez CM; Yi L; Romano JG; Perez E; Tyson BA; Ayodele M; Asdaghi N; Gardener H; Rose DZ; Garcia EJ; Zevallos JC; Foster D; Robichaux M; Waddy SP; Sacco RL; Rundek T;
    Stroke; 2017 Aug; 48(8):2192-2197. PubMed ID: 28706119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous thrombolysis for patients with in-hospital stroke onset: propensity-matched analysis from the Safe Implementation of Treatments in Stroke-East registry.
    Tsivgoulis G; Katsanos AH; Kadlecová P; Czlonkowska A; Kobayashi A; Brozman M; Švigelj V; Csiba L; Fekete K; Kõrv J; Demarin V; Vilionskis A; Jatuzis D; Krespi Y; Karapanayiotides T; Giannopoulos S; Mikulik R
    Eur J Neurol; 2017 Dec; 24(12):1493-1498. PubMed ID: 28888075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.